Home Trending Stocks Cocrystal Pharma, Inc. (COCP) Stock Skyrocketed Following Promising Updates on Covid-19 Drug...

Cocrystal Pharma, Inc. (COCP) Stock Skyrocketed Following Promising Updates on Covid-19 Drug Development

Cocrystal Pharma, Inc. (COCP) stock prices were up by a monumental 72.58% as of the market closing on may 4th 2021, bringing the price per share up to USD$2.14 at the end of the trading day. Subsequent pre-market fluctuations saw the stock fall by a significant 22.9%, bringing it down to USD$1.65.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Covid-19 Treatment Program

COCP was already in the business of the discovery and development of novel antiviral therapies, designed to target the replication mechanisms of a range of virus types, including coronaviruses. The company recently announced progress in the development of broad-spectrum antiviral drug candidates that target coronaviruses, including SARS-CoV-2, the virus that causes Covid-19. The Covid-19 program was initiated in March of 2020 and has since been expanded with further development and licensing.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Success of Treatments in Development

As the global pandemic rages on while the world hurtles towards universal immunizations, COCP is aggressively developing therapies for Covid-19. The company has allocated resources towards developing protease inhibitors for prophylactic and therapeutic use in Covid-19 cases, with the drug candidates bind to an active site of the virus protease that is responsible for Covid-19’s viral replication. Using proprietary high-res x-ray co-crystal structures, the company further confirmed the interaction between the drug candidate and the conserved region of the proteases of various coronaviruses.

Circumventing Issues Posed by Covid-19 Variants

As a result of the drug candidates’ innovate mechanism of action, COCP anticipates the protease inhibitors being developed to be effective against the various strains of SARS-CoV-2 springing up across the world. This is despite variants of Covid-19 possibly being more contagious and immune to existing vaccines and therapies.

Promising Scope of CDI-45205

December 2020 saw the announcement of the selection of CDI-45205 as COCP’s leading coronavirus development candidate, among many, following the acquisition of an exclusive licensing agreement with Kansas State University Research Foundation earlier in 2020. The drug exhibited promising bioavailability in rodent pharmacokinetic studies and showed no signs of cytotoxicity against a number of human cell lines. CDI-45205 also has demonstrably strong synergistic effects with the FDA-approved Covid-19 drug remdesivir.

Expanding Covid-19 Drug Candidates

The company has continued to leverage its expertise in antiviral development to facilitate the launch of a second Covid-19 program. Using proprietary COCP technology and their drug discovery platform, the company is aiming to develop additional antiviral compounds that will aid in the global efforts towards universal immunizations.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for COCP

With the world hurtling towards a resolution to the global pandemic, COCP is at the forefront of the race to supply nearly every economy in the world with Covid-19 treatments, armed with its recent generation of USD$40 million in capital from a recent underwriting agreement. Current and potential investors are hopeful that the company will be able to leverage its resources to capitalize on an unfortunate opportunity that was already well within its area of expertise, thus ushering in unprecedented increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Antero Resources Corp. (AR) stock fell during after-market. Here’s to know why?

Antero Resources Corp. (NASDAQ: AR) stock plunged by 0.58% at last close while the AR stock price declines by 6.59% in the after-hours trading...

Why Electrameccanica Vehicles Corp. (SOLO) stock performed well on Wednesday?

Electrameccanica Vehicles Corp. (SOLO) shares gained 5.71% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $3.70 per share. in...

Related News

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam